{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:51:25Z","timestamp":1783785085248,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX110-11010BI"],"award-info":[{"award-number":["NHRI-EX110-11010BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-21-070"],"award-info":[{"award-number":["BCRF-21-070"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2314-B-039-025-MY2"],"award-info":[{"award-number":["MOST 109-2314-B-039-025-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2639-B-039-001-ASP"],"award-info":[{"award-number":["MOST 110-2639-B-039-001-ASP"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2320-B-039-065"],"award-info":[{"award-number":["110-2320-B-039-065"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2314-B-039-043-MY3"],"award-info":[{"award-number":["110-2314-B-039-043-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012544","name":"China Medical University, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007107","name":"Korea Advanced Institute of Science and Technology","doi-asserted-by":"publisher","award":["2021R1A4A1031856"],"award-info":[{"award-number":["2021R1A4A1031856"]}],"id":[{"id":"10.13039\/501100007107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007107","name":"Korea Advanced Institute of Science and Technology","doi-asserted-by":"publisher","award":["2020R1C1C1005631"],"award-info":[{"award-number":["2020R1C1C1005631"]}],"id":[{"id":"10.13039\/501100007107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["C1090615012"],"award-info":[{"award-number":["C1090615012"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["CMU108-YTY-04"],"award-info":[{"award-number":["CMU108-YTY-04"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["5T32CA186892"],"award-info":[{"award-number":["5T32CA186892"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jbc.2022.101817","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T20:43:55Z","timestamp":1646858635000},"page":"101817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer"],"prefix":"10.1016","volume":"298","author":[{"given":"Jong-Ho","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chuan","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-6729","authenticated-orcid":false,"given":"Ying-Nai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-5323","authenticated-orcid":false,"given":"Chie-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiya","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woei-Cherng","family":"Shyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Wen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Ru","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jielin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Oe","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dihua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Bin","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2022.101817_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. primers"},{"key":"10.1016\/j.jbc.2022.101817_bib2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s43018-021-00211-x","article-title":"Finding the positive in triple-negative breast cancer","volume":"2","author":"Carey","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jbc.2022.101817_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: From TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbc.2022.101817_bib4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","volume":"129","author":"Gruosso","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jbc.2022.101817_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PPO.0000000000000497","article-title":"Immunotherapy in triple-negative breast cancer","volume":"27","author":"Emens","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.jbc.2022.101817_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12885-017-3916-y","article-title":"Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbc.2022.101817_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.jbc.2022.101817_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2022.101817_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-020-01304-4","article-title":"A\u00a0comparability study of natural and deglycosylated PD-L1 levels in lung cancer: Evidence from immunohistochemical analysis","volume":"20","author":"Mei","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbc.2022.101817_bib10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrm856","article-title":"Mechanisms and functions of Eph and ephrin signalling","volume":"3","author":"Kullander","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jbc.2022.101817_bib11","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009159","article-title":"Eph receptor signaling and ephrins","volume":"5","author":"Lisabeth","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jbc.2022.101817_bib12","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1038\/sj.onc.1203856","article-title":"Eph receptors and ephrin ligands: Embryogenesis to tumorigenesis","volume":"19","author":"Dodelet","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2022.101817_bib13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/80606","article-title":"Disruption of Eph\/ephrin signaling affects migration and proliferation in the adult subventricular zone","volume":"3","author":"Conover","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jbc.2022.101817_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: Bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2022.101817_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10555-012-9352-1","article-title":"The Eph\/Ephrin family in cancer metastasis: Communication at the service of invasion","volume":"31","author":"Kandouz","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jbc.2022.101817_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbagen.2005.01.011","article-title":"Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis","volume":"1723","author":"Aasheim","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbc.2022.101817_bib17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2014.06.010","article-title":"Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers","volume":"189","author":"Nagano","year":"2014","journal-title":"J.\u00a0Control Release"},{"key":"10.1016\/j.jbc.2022.101817_bib18","doi-asserted-by":"crossref","first-page":"30344","DOI":"10.18632\/oncotarget.15910","article-title":"Isoform expression patterns of EPHA10 protein mediate breast cancer progression by regulating the E-Cadherin and beta-catenin complex","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2022.101817_bib19","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1111\/cas.14568","article-title":"The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells","volume":"111","author":"Shin","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jbc.2022.101817_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bbrc.2014.06.007","article-title":"Eph receptor A10 has a potential as a target for a prostate cancer therapy","volume":"450","author":"Nagano","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2022.101817_bib21","first-page":"512","article-title":"EphA10 and EphB3 are prognostic markers in gallbladder squamous cell\/adenosquamous carcinomas and adenocarcinomas","volume":"11","author":"Yan","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.jbc.2022.101817_bib22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/cam4.156","article-title":"Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients","volume":"2","author":"Nagano","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.jbc.2022.101817_bib23","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-18-0040","article-title":"Juxtacrine signaling inhibits antitumor immunity by upregulating PD-L1 expression","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.101817_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/cancers10090295","article-title":"Epigenetic crosstalk between the tumor microenvironment and ovarian cancer cells: A therapeutic road less traveled","volume":"10","author":"Klymenko","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2022.101817_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.molimm.2017.04.012","article-title":"Epigenetics and immunotherapy: The current state of play","volume":"87","author":"Dunn","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jbc.2022.101817_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.jbc.2022.101817_bib27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cells9010046","article-title":"Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses","volume":"9","author":"Anfray","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jbc.2022.101817_bib28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: Immune-suppressive cells that impair antitumor immunity and are Sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg","year":"2018","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2022.101817_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2022.101817_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J.\u00a0Biomed. Sci."},{"key":"10.1016\/j.jbc.2022.101817_bib31","doi-asserted-by":"crossref","first-page":"26240","DOI":"10.1038\/srep26240","article-title":"Targeting membrane proteins for antibody discovery using phage display","volume":"6","author":"Jones","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2022.101817_bib32","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1038\/s41388-019-0931-2","article-title":"Eph receptor signalling: From catalytic to non-catalytic functions","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2022.101817_bib33","series-title":"Handbook of Anticancer Pharmacokinetics and Pharmacodynamics","first-page":"475","article-title":"Pharmacokinetics of antibodies and immunotoxins in mice and humans","author":"Ghetie","year":"2014"},{"key":"10.1016\/j.jbc.2022.101817_bib34","first-page":"106","article-title":"Understanding waterfall plots","volume":"3","author":"Gillespie","year":"2012","journal-title":"J.\u00a0Adv. Pract. Oncol."},{"key":"10.1016\/j.jbc.2022.101817_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","article-title":"Harnessing innate immunity in cancer therapy","volume":"574","author":"Demaria","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2022.101817_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fimmu.2018.00014","article-title":"Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy","volume":"9","author":"Durgeau","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2022.101817_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: Safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbc.2022.101817_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbc.2022.101817_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jbc.2022.101817_bib40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.omtm.2020.01.012","article-title":"A\u00a0high-throughput method for characterizing novel chimeric antigen receptors in Jurkat cells","volume":"16","author":"Bloemberg","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jbc.2022.101817_bib41","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.xpro.2020.100174","article-title":"Preclinical testing of CAR T cells in a patient-derived xenograft model of glioblastoma","volume":"1","author":"Tatari","year":"2020","journal-title":"STAR Protoc."},{"key":"10.1016\/j.jbc.2022.101817_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jbc.2022.101817_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-20-0405","article-title":"Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition","volume":"9","author":"Xia","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jbc.2022.101817_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: A comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jbc.2022.101817_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2022.101817_bib46","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.jbc.2022.101817_bib47","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016758","article-title":"Clathrin-independent pathways of endocytosis","volume":"6","author":"Mayor","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jbc.2022.101817_bib48","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/bioinformatics\/btu097","article-title":"ZDOCK server: Interactive docking prediction of protein-protein complexes and symmetric multimers","volume":"30","author":"Pierce","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jbc.2022.101817_bib49","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/bioinformatics\/btu190","article-title":"Improving B-cell epitope prediction and its application to global antibody-antigen docking","volume":"30","author":"Krawczyk","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jbc.2022.101817_bib50","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: Homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jbc.2022.101817_bib51","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/19420862.2016.1205773","article-title":"ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation","volume":"8","author":"Leem","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.jbc.2022.101817_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-3-319-32805-8_6","article-title":"Therapeutic antibodies in cancer therapy","volume":"917","author":"Gasser","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jbc.2022.101817_bib53","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1042\/BST20130104","article-title":"Receptor tyrosine kinases with intracellular pseudokinase domains","volume":"41","author":"Mendrola","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jbc.2022.101817_bib54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jbc.2022.101817_bib55","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrclinonc.2010.185","article-title":"HER2 and hormone receptor-positive breast cancer--blocking the right target","volume":"8","author":"Cortes","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jbc.2022.101817_bib56","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1189\/jlb.0709497","article-title":"Activation of EphA receptors on CD4+CD45RO+ memory cells stimulates migration","volume":"87","author":"Holen","year":"2010","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.jbc.2022.101817_bib57","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/eji.200737111","article-title":"Ephrin-A1 stimulates migration of CD8+CCR7+ T lymphocytes","volume":"37","author":"Hjorthaug","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jbc.2022.101817_bib58","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1182\/blood-2004-08-2981","article-title":"Ephrin-A1 binding to CD4+ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2","volume":"105","author":"Aasheim","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2022.101817_bib59","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3389\/fimmu.2019.01473","article-title":"Emerging roles for Eph receptors and Ephrin ligands in immunity","volume":"10","author":"Darling","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822002575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822002575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:52:47Z","timestamp":1777409567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925822002575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0021925822002575"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2022.101817","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2022.101817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101817"}}